Relvar Ellipta 92/22 mcg

Relvar Ellipta 92/22 mcg is a medicine authorised by Swissmedic under authorisation number 62969. The authorisation holder is GlaxoSmithKline AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 09 January 2014 and the authorisation is valid without a time limit. ATC code R03AK10 places the medicine in the group Drugs for obstructive airway diseases.

  • Dispensing category B
  • Authorisation number 62969
  • ATC R03AK10
  • Synthetic medicines
Authorisation data
Authorisation number62969
NameRelvar Ellipta 92/22 mcg
Full nameRelvar Ellipta 92/22 mcg, Einzeldosiertes Pulver zur Inhalation
Authorisation holderGlaxoSmithKline AG
Medicinal product codeSynthetic medicines
Dispensing categoryB · Prescription only
ATC codeR03AK10
First authorisation09 January 2014
Authorisation validityunlimited
Strengths
No.NameDispensing categoryAuthorisation date
1Relvar Ellipta 92/22 mcg, Einzeldosiertes Pulver zur InhalationB09 January 2014
2Relvar Ellipta 184/22 mcg, Einzeldosiertes Pulver zur InhalationB09 January 2014

Scroll the table sideways

Pack sizes
Pack codeQuantityUnitATCIT codeDispensing category
130Einzeldose(n)R03AK1003.04.3.B
33 x 30Einzeldose(n)R03AK1003.04.3.B
230Einzeldose(n)R03AK1003.04.3.B
43 x 30Einzeldose(n)R03AK1003.04.3.B

Scroll the table sideways

Other medicines from this authorisation holder

Frequently asked questions

Is Relvar Ellipta 92/22 mcg authorised in Switzerland?

Yes. Relvar Ellipta 92/22 mcg is authorised by Swissmedic under authorisation number 62969, data as of 01 September 2026. The authorisation is valid without a time limit.

Which dispensing category does Relvar Ellipta 92/22 mcg have?

Relvar Ellipta 92/22 mcg is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.

Who is the authorisation holder of Relvar Ellipta 92/22 mcg?

The authorisation holder is GlaxoSmithKline AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.

Sources

Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.

Authorisation in Switzerland?

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissmedicinesdirectory.com